How to balance cardiorenometabolic benefits and risks of statins

Atherosclerosis

Volumn 235, Issue 2, 2014, Pages 644-648

  Lim, Soo ^a   Oh, Pyung Chun ^b,c   Sakuma, Ichiro ^d   Koh, Kwang Kon ^b,c  

^a Seoul National University Bundang Hospital   (South Korea)

^b Gachon University College of Medicine   (South Korea)

^c Gachon Cardiovascular Research Institute   (South Korea)

^d Hokko Memorial Clinic   (Japan)

Author keywords

Benefits and risks; Cardiovascular disease; Diabetes; Renal injury; Statins

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; INSULIN;

ACUTE KIDNEY FAILURE; CARDIORENOMETABOLIC RISK; CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DRUG EFFECT; DRUG INDICATION; GLYCEMIC CONTROL; HUMAN; INSULIN RESISTANCE; KIDNEY DISEASE; PRIMARY PREVENTION; PRIORITY JOURNAL; REVIEW; RISK; RISK BENEFIT ANALYSIS; RISK REDUCTION; TREATMENT PLANNING; ANIMAL; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; CHEMICALLY INDUCED; CONTRAINDICATIONS; PHYSIOLOGY; RISK ASSESSMENT;

ACUTE KIDNEY INJURY; ANIMALS; ASIAN CONTINENTAL ANCESTRY GROUP; CARDIOVASCULAR DISEASES; DIABETES MELLITUS; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; INSULIN RESISTANCE; RISK ASSESSMENT;

EID: 84921534753     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2014.06.001     Document Type: Review

References (70)

1. Baigent C., Blackwell L., Emberson J., Holland L.E., Reith C., Bhala N., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681.
2. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S). Lancet 1994, 344:1383-1389.
3. Colhoun H.M., Betteridge D.J., Durrington P.N., Hitman G.A., Neil H.A., Livingstone S.J., et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet 2004, 364:685-696.
4. Ford I., Murray H., Packard C.J., Shepherd J., Macfarlane P.W., Cobbe S.M. Long-term follow-up of the west of scotland coronary prevention study. NEngl J Med 2007, 357:1477-1486.
5. Koh K.K. Effects of statins on vascular wall: vasomotor function, inflammation, and plaque stability. Cardiovasc Res 2000, 47:648-657.
6. Koh K.K. Effects of HMG-CoA reductase inhibitor on hemostasis. Int J Cardiol 2000, 76:23-32.
7. Sparrow C.P., Burton C.A., Hernandez M., Mundt S., Hassing H., Patel S., et al. Simvastatin has anti-inflammatory and antiatherosclerotic activities independent of plasma cholesterol lowering. Arterioscler Thromb Vasc Biol 2001, 21:115-121.
8. Joo S.J. Anti-inflammatory effects of statins beyond cholesterol lowering. Korean Circ J 2012, 42:592-594.
9. Koh K.K., Quon M.J., Han S.H., Chung W.J., Ahn J.Y., Seo Y.H., et al. Additive beneficial effects of losartan combined with simvastatin in the treatment of hypercholesterolemic, hypertensive patients. Circulation 2004, 110:3687-3692.
10. Koh K.K., Han S.H., Oh P.C., Shin E.K., Quon M.J. Combination therapy for treatment or prevention of atherosclerosis: focus on the lipid-RAAS interaction. Atherosclerosis 2010, 209:307-313.
11. Tolman K.G. The liver and lovastatin. Am J Cardiol 2002, 89:1374-1380.
12. Ucar M., Mjorndal T., Dahlqvist R. HMG-CoA reductase inhibitors and myotoxicity. Drug Saf 2000, 22:441-457.
13. Goldstein L.B., Amarenco P., Szarek M., Callahan A., Hennerici M., Sillesen H., et al. Hemorrhagic stroke in the stroke prevention by aggressive reduction in cholesterol levels study. Neurology 2008, 70:2364-2370.
14. Sheikh-Ali A.A., Maddukuri P.V., Han H., Karas R.H. Effect of the magnitude of lipid lowering on risk of elevated liver enzymes, rhabdomyolysis, and cancer: insights from large randomized statin trials. JAm Coll Cardiol 2007, 50:409-418.
15. Dale K.M., Coleman C.I., Henyan N.N., Kluger J., White C.M. Statins and cancer risk: a meta-analysis. JAMA 2006, 295:74-80.
16. Desai P., Chlebowski R., Cauley J.A., Manson J.E., Wu C., Martin L.W., et al. Prospective analysis of association between statin use and breast cancer risk in the women's health initiative. Cancer Epidemiol Biomarkers Prev 2013, 22:1868-1876.
17. Singh P.P., Singh S. Statins are associated with reduced risk of gastric cancer: a systematic review and meta-analysis. Ann Oncol 2013, 24:1721-1730.
18. Tsan Y.T., Lee C.H., Wang J.D., Chen P.C. Statins and the risk of hepatocellular carcinoma in patients with hepatitis B virus infection. JClin Oncol 2012, 30:623-630.
19. Nielsen S.F., Nordestgaard B.G., Bojesen S.E. Statin use and reduced cancer-related mortality. NEngl J Med 2012, 367:1792-1802.
20. Lan S., Bimal R.S., Eric M.R., Thomas L., Wojdyla D., Diem P., et al. Role of diuretics, beta-blockers, and statins in increasing the risk of diabetes in patients with impaired glucose tolerance: reanalysis of data from the NAVIGATOR study. BMJ 2013, 347.
21. Preiss D., Seshasai S.R., Welsh P., Murphy S.A., Ho J.E., Waters D.D., et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA 2011, 305:2556-2564.
22. Ridker P.M., Pradhan A., MacFadyen J.G., Libby P., Glynn R.J. Cardiovascular benefits and diabetes risks of statin therapy in primary prevention: an analysis from the JUPITER trial. Lancet 2012, 380:565-571.
23. Carter A.A., Gomes T., Camacho X., Juurlink D.N., Shah B.R., Mamdani M.M. Risk of incident diabetes among patients treated with statins: population based study. BMJ 2013, 346:f2610.
24. Culver A.L., Ockene I.S., Balasubramanian R., Olendzki B.C., Sepavich D.M., Wactawski-Wende J., et al. Statin use and risk of diabetes mellitus in postmenopausal women in the women's health initiative. Arch Intern Med 2012, 172:144-152.
25. Koh K.K., Quon M.J., Han S.H., Lee Y., Ahn J.Y., Kim S.J., et al. Simvastatin improves flow-mediated dilation but reduces adiponectin levels and insulinsensitivity in hypercholesterolemic patients. Diabetes Care 2008, 31:776-782.
26. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Shin E.K. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. JAm Coll Cardiol 2010, 55:1209-1216.
27. Sattar N., Preiss D., Murray H.M., Welsh P., Buckley B.M., de Craen A.J., et al. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet 2010, 375:735-742.
28. Waters D.D., Ho J.E., Boekholdt S.M., DeMicco D.A., Kastelein J.J., Messig M., et al. Cardiovascular event reduction versus new-onset diabetes during atorvastatin therapy: effect of baseline risk factors for diabetes. JAm Coll Cardiol 2013, 61:148-152.
29. Dormuth C.R., Hemmelgarn B.R., Paterson J.M., James M.T., Teare G.F., Raymond C.B., et al. Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases. BMJ 2013, 346:f880.
30. Koh K.K., Quon M.J., Han S.H., Lee Y., Kim S.J., Park J.B., et al. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis 2009, 204:483-490.
31. Koh K.K., Quon M.J., Sakuma I., Han S.H., Choi H., Lee K., et al. Differential metabolic effects of rosuvastatin and pravastatin in hypercholesterolemic patients. Int J Cardiol 2013, 166:509-515.
32. Coleman C.I., Reinhart K., Kluger J., White C.M. The effect of statins on the development of new-onset type 2 diabetes: a meta-analysis of randomized controlled trials. Curr Med Res Opin 2008, 24:1359-1362.
33. Yoon J.S., Lee H.W. Diabetogenic effect of statins: a double-edged sword?. Diabetes Metab J 2013, 37:415-422.
34. Yada T., Nakata M., Shiraishi T., Kakei M. Inhibition by simvastatin, but not pravastatin, of glucose-induced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999, 126:1205-1213.
35. Liao J.K. Isoprenoids as mediators of the biological effects of statins. JClin Invest 2002, 110:285-288.
36. Chamberlain L.H. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett 2001, 507:357-361.
37. Koh K.K., Sakuma I., Quon M.J. Differential metabolic effects of distinct statins. Atherosclerosis 2011, 215:1-8.
38. Kanda M., Satoh K., Ichihara K. Effects of atorvastatin and pravastatin on glucose tolerance in diabetic rats mildly induced by streptozotocin. Biol Pharm Bull 2003, 26:1681-1684.
39. Mallinson J.E., Constantin-Teodosiu D., Sidaway J., Westwood F.R., Greenhaff P.L. Blunted Akt/FOXO signalling and activation of genes controlling atrophy and fuel use in statin myopathy. JPhysiol 2009, 587:219-230.
40. Nakata M., Nagasaka S., Kusaka I., Matsuoka H., Ishibashi S., Yada T. Effects ofstatins on the adipocyte maturation and expression of glucose transporter 4(SLC2A4): implications in glycaemic control. Diabetologia 2006, 49:1881-1892.
41. Coritsidis G., Rifici V., Gupta S., Rie J., Shan Z.H., Neugarten J., et al. Preferential binding of oxidized LDL to rat glomeruli invivo and cultured mesangial cells invitro. Kidney Int 1991, 39:858-866.
42. Kramer-Guth A., Nauck M., Pavenstädt H., Königer M., Wieland H., Schollmeyer P., et al. Preferential uptake of intermediate-density lipoproteins from nephrotic patients by human mesangial and liver cells. JAm Soc Nephrol 1994, 5:1081-1090.
43. Rovin B.H., Tan L.C. LDL stimulates mesangial fibronectin production and chemoattractant expression. Kidney Int 1993, 43:218-225.
44. Kim S.I., Kim H.J., Han D.C., Lee H.B. Effect of lovastatin on small GTP binding proteins and on TGF-beta1 and fibronectin expression. Kidney Int Suppl 2000, 77:S88-S92.
45. Rikitake Y., Liao J.K. Rho GTPases, statins, and nitric oxide. Circ Res 2005, 97:1232-1235.
46. Collins R., Armitage J., Parish S., Sleigh P., Peto R. MRC/BHF heart protection study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet 2003, 361:2005-2016.
47. Tonelli M., Moye L., Sacks F.M., Cole T., Curhan G.C. Effect of pravastatin on loss of renal function in people with moderate chronic renal insufficiency and cardiovascular disease. JAm Soc Nephrol 2003, 14:1605-1613.
48. Athyros V.G., Mikhailidis D.P., Papageorgiou A.A., Symeonidis A.N., Pehlivanidis A.N., Bouloukos V.I., et al. The effect of statins versus untreated dyslipidaemia on renal function in patients with coronary heart disease. A subgroup analysis of the Greek atorvastatin and coronary heart disease evaluation (GREACE) study. JClin Pathol 2004, 57:728-734.
49. Kuwabara M., Kubo T., Bando K., Hirakawa Y., Kitaoka H., Nishinaga M., et al. 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors prevent the progression of renal dysfunction in Japanese hypertensive patients. Geriatr Gerontol Int 2010, 10:219-224.
50. Wolfe S.M. Dangers of rosuvastatin identified before and after FDA approval. Lancet 2004, 363:2189-2190.
51. Kiortsis D.N., Filippatos T.D., Mikhailidis D.P., Elisaf M.S., Liberopoulos E.N. Statin-associated adverse effects beyond muscle and liver toxicity. Atherosclerosis 2007, 195:7-16.
52. Hippisley-Cox J., Coupland C. Unintended effects of statins in men and women in England and wales: population based cohort study using the QResearch database. BMJ 2010, 340:c2197.
53. McMurray J.J., Dunselman P., Wedel H., Cleland J.G., Lindberg M., Hjalmarson A., et al. Coenzyme Q10, rosuvastatin, and clinical outcomes in heart failure: a pre-specified substudy of CORONA (controlled rosuvastatin multinational study in heart failure). JAm Coll Cardiol 2010, 56:1196-1204.
54. Marcoff L., Thompson P.D. The role of coenzyme Q10 in statin-associated myopathy: a systematic review. JAm Coll Cardiol 2007, 49:2231-2237.
55. Sourris K.C., Harcourt B.E., Tang P.H., Morley A.L., Huynh K., Penfold S.A., et al. Ubiquinone (coenzyme Q10) prevents renal mitochondrial dysfunction in an experimental model of type 2 diabetes. Free Radic Biol Med 2012, 52:716-723.
56. Peerapanyasut W., Thamprasert K., Wongmekiat O. Ubiquinol supplementation protects against renal ischemia and reperfusion injury in rats. Free Radic Res 2014, 48:180-189.
57. Sheikh-Ali A.A., Ambrose M.S., Kuvin J.T., Karas R.H. The safety of rosuvastatin as used in common clinical practice: a postmarketing analysis. Circulation 2005, 111:3051-3057.
58. Mihaylova B., Emberson J., Blackwell L., Keech A., Simes J., Barnes E.H., et al. The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials. Lancet 2012, 380:581-590.
59. Catapano A.L., Reiner Z., De Backer G., Graham I., Taskinen M.R., Wiklund O., et al. ESC/EAS guidelines for the management of dyslipidaemias: the task force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Atherosclerosis 2011, 217:1-44.
60. Stone N.J., Robinson J., Lichtenstein A.H., Bairey Merz C.N., Lloyd-Jones D.M., Blum C.B., et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association task force on practice guidelines. Circulation 2013, [Epub a head of print].
61. Koh K.K., Quon M.J. The importance of considering alternative or combination strategies for lowering LDL-C. Int J Cardiol 2009, 136:115-119.
62. Koh K.K., Quon M.J. Targeting converging therapeutic pathways to overcome hypertension. Int J Cardiol 2009, 132:297-299.
63. Koh K.K., Lim S., Sakuma I., Quon M.J. Caveats to aggressive lowering of lipids by specific statins. Int J Cardiol 2012, 154:97-101.
64. Lim S., Sakuma I., Quon M.J., Koh K.K. Potentially important considerations in choosing specific statin treatments to reduce overall morbidity and mortality. Int J Cardiol 2013, 167:1696-1702.
65. Lim S., Sakuma I., Quon M.J., Koh K.K. Differential metabolic actions of specific statins: clinical and therapeutic considerations. Antioxid Redox Signal 2013, 20:1286-1299.
66. Lim S., Park Y.M., Sakuma I., Koh K.K. How to control residual cardiovascular risk despite statin treatment: focusing on HDL-cholesterol. Int J Cardiol 2012, 166:8-14.
67. -/- mice. Korean Circ J 2012, 42:543-550.
68. Lee H.Y., Sakuma I., Ihm S.H., Goh C.W., Koh K.K. Statins and renin-angiotensin system inhibitor combination treatment to prevent cardiovascular disease. Circ J 2014, 78:281-287.
69. Goldstein M.R., Mascitelli L. Do statins cause diabetes?. Curr Diab Rep 2013, 13:381-390.
70. Huseyin N., John P.A.I. Comparative effectiveness of exercise and drug interventions on mortality outcomes: metaepidemiological study. BMJ 2013, 347.